When a cataract patient chooses a premium intraocular lens, the part of that procedure that corrects the cataract is covered by Medicare, and the upgrade to a lens that also corrects astigmatism or restores a range of vision is paid entirely out of pocket. The practice sets that price. Medicare does not touch it. Premium lens attach rates already run around 15 to 18 percent of cataract patients and have realistic room to climb past 30 percent as the technology improves and the aging population grows wealthier, according to vision industry market analysis. This is the layer of ophthalmology revenue that most allocators model at zero, and it is the layer with the most pricing power and the least regulatory exposure in the entire business.

Why Cash-Pay Revenue Changes the Ophthalmology Math

Reimbursement revenue is set by a formula an investor cannot influence and a government can cut. Cash-pay revenue is set by the practice, the surgeon's reputation, and the patient's willingness to pay for a better outcome. The two streams behave nothing alike, and conflating them is one of the most common mistakes in valuing a surgical practice. One is a regulated number that grinds lower in real terms most years as reimbursement updates fail to keep pace with costs. The other is a market price that rises with demand, with affluence, and with the quality of the practice delivering it.

A cataract base of four million procedures a year, climbing toward six million by 2030, sitting underneath a cash-pay upgrade layer with rising attach rates, is a compounding structure hiding inside a business most people think of as purely Medicare-driven. The cataract gets the patient in the door under Medicare coverage. The upgrade conversation is where the pricing power lives, and every percentage point of improvement in the attach rate flows almost entirely to margin, because the surgical capacity and the patient relationship already exist. The practice is not acquiring a new customer to sell the upgrade. It is offering a better option to a patient who is already on the table.

How an Ophthalmology Platform Builds the Cash-Pay Layer

Capturing the cash-pay layer is an operating skill rather than a windfall that arrives on its own. It takes surgeon training in the newer lens technologies, patient education delivered well before the day of surgery, the right equipment, and a practice culture comfortable discussing an out-of-pocket option without applying pressure that erodes trust. Practices that do this well convert a meaningfully higher share of patients to premium lenses, and they do it while maintaining the patient relationships that drive referrals. Practices that do it poorly leave the revenue on the table or, worse, damage trust by pushing upgrades that patients later regret.

A permanent holder has every reason to invest in that capability, because the return compounds for as long as the platform owns the practice, which is indefinitely. A ten-year fund has a weaker incentive, because the payoff from patiently building a premium-conversion culture often arrives in years that fall after the fund needs to sell. The cash-pay layer rewards the owner willing to build the capability slowly, train the surgeons properly, and hold the asset long enough to harvest the compounding, which describes the permanent holder almost by definition and describes the fund almost never.

What Allocators Miss When They Model Ophthalmology

An allocator who values an ophthalmology platform on Medicare reimbursement alone is valuing the floor and ignoring the upside. The premium lens layer is real revenue, it is growing, it carries genuine pricing power, and it is insulated from the reimbursement formula that limits the rest of the business. Medicare cannot cut it, cannot cap it, and cannot touch it, which is exactly why it deserves its own line in the model rather than being folded into an assumption about reimbursement.

The platforms that understand this are building the upgrade capability now, ahead of the volume wave and ahead of the wealth transfer that will make the upgrade more affordable to more patients. The ones that do not will spend the next decade leaving the highest-margin, most defensible revenue in ophthalmology on the table, while modeling the business as if its only revenue came from a fee schedule the government rewrites every year. The cash-pay layer is where a sophisticated owner separates the platform that merely collects reimbursement from the one that builds a durable, growing, pricing-power business on top of it.

Why the Ophthalmology Cash-Pay Layer Hedges the Reimbursement Side

The contrast with the reimbursement side sharpens the point. Medicare physician payments have fallen meaningfully in real terms over the past two decades as fee updates failed to keep pace with inflation and operating costs, which is the slow squeeze that pushes independent practices toward a sale in the first place. The cash-pay layer moves in the opposite direction, because it is priced in a market rather than set by a formula, and it rises with the affluence of the patient population rather than falling with the reimbursement schedule. A platform that grows its cash-pay revenue is building a hedge against the exact pressure that erodes the reimbursement side.

The math of that hedge is worth making concrete. A premium lens upgrade carries an out-of-pocket price that commonly runs into the low thousands of dollars per eye above the Medicare-covered base, set by the practice rather than the fee schedule. On a base of two thousand cataract patients a year, moving the premium attach rate from 15 percent to 25 percent means roughly two hundred additional patients choosing the upgrade annually. Even at a conservative incremental price per eye, that single ten-point improvement in conversion adds a six-figure stream of high-margin, non-Medicare revenue that did not exist before, and it compounds every year the volume base grows. None of that requires acquiring a single new patient or performing a single additional surgery. It requires a practice culture and a training program that convert patients already on the table, which is exactly the kind of slow operating improvement a permanent holder is built to make and a fund is structurally disinclined to fund.

The two streams do not just behave differently. They move in opposite directions, which means the cash-pay layer is not only the highest-margin revenue in the business but also the part that protects the owner from the structural decline in the regulated half. An allocator who models only the reimbursement line is therefore making two errors at once. The first is undervaluing the upside by ignoring a growing, high-margin stream. The second is overstating the risk by treating the whole business as exposed to reimbursement cuts, when the fastest-growing part of it is specifically insulated from them. Correcting both errors reframes the platform from a reimbursement-dependent business into one with a built-in hedge and a pricing-power engine the government cannot reach.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com